Two genomic studies could yield more effective, less toxic immunotherapies

by Institut CurieTE-Exon splicing junctions can help differentiate tumors from healthy tissue. Credit: Verge Scientific Communications / Antonela Merlotti / Marianne Burbage / Benjamin SadaccaMnemo Th

Updated on: December 28,2023

Two genomic studies could yield more effective, less toxic immunotherapies

by Institut CurieTE-Exon splicing junctions can help differentiate tumors from healthy tissue. Credit: Verge Scientific Communications / Antonela Merlotti / Marianne Burbage / Benjamin SadaccaMnemo Th

Updated on:December 28,2023

Special RNA shown to suppress the formation of breast cancer cells

JANUARY 16, 2024by Sebastian Hollstein,Friedrich Schiller University of JenaCredit:Cell Reports(2024). DOI: 10.1016/j.celrep.2023.113644Breast cancer is the most common cancer in wom

Updated on: March 25,2024

Special RNA shown to suppress the formation of breast cancer cells

JANUARY 16, 2024by Sebastian Hollstein,Friedrich Schiller University of JenaCredit:Cell Reports(2024). DOI: 10.1016/j.celrep.2023.113644Breast cancer is the most common cancer in wom

Updated on:March 25,2024

Study finds increase in women 65 and older dying of cervical cancer

by Stephanie Winn,UC DavisCredit: Unsplash/CC0 Public DomainA new study conducted by UC Davis Comprehensive Cancer Center researchers shows an alarming number of California women 65 and older ar

Updated on: January 23,2024

Study finds increase in women 65 and older dying of cervical cancer

by Stephanie Winn,UC DavisCredit: Unsplash/CC0 Public DomainA new study conducted by UC Davis Comprehensive Cancer Center researchers shows an alarming number of California women 65 and older ar

Updated on:January 23,2024

Driving rhabdomyosarcoma into differentiation through targeted transformation of tumor cells

by Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI)Induction of myogenic differentiation and reduction of cell division in rhabdomyosarcoma cells after reducing of the amount

Updated on: January 07,2024

Driving rhabdomyosarcoma into differentiation through targeted transformation of tumor cells

by Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI)Induction of myogenic differentiation and reduction of cell division in rhabdomyosarcoma cells after reducing of the amount

Updated on:January 07,2024

A new tool to screen drugs that target loss of tumor suppressor genes

by Ludwig Cancer ResearchGraphical abstract. Credit:iScience(2022). DOI: 10.1016/j.isci.2022.104437In a May publication iniScience, researchers led by Ludwig Johns Hopkins's

Updated on: January 30,2024

A new tool to screen drugs that target loss of tumor suppressor genes

by Ludwig Cancer ResearchGraphical abstract. Credit:iScience(2022). DOI: 10.1016/j.isci.2022.104437In a May publication iniScience, researchers led by Ludwig Johns Hopkins's

Updated on:January 30,2024

Research uncovers alternate mechanism for producing key protein in metastatic prostate cancer

by Dana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainLike the better-known prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA) is a biomarker that can tell physi

Updated on: February 18,2024

Research uncovers alternate mechanism for producing key protein in metastatic prostate cancer

by Dana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainLike the better-known prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA) is a biomarker that can tell physi

Updated on:February 18,2024

Enhanced recovery program shown to successfully reduce opioid use after pancreatic cancer surgery

by University of Texas M. D. Anderson Cancer CenterCredit: Unsplash/CC0 Public DomainBy improving hospital care pathways, researchers from The University of Texas MD Anderson Cancer Center succes

Updated on: January 30,2024

Enhanced recovery program shown to successfully reduce opioid use after pancreatic cancer surgery

by University of Texas M. D. Anderson Cancer CenterCredit: Unsplash/CC0 Public DomainBy improving hospital care pathways, researchers from The University of Texas MD Anderson Cancer Center succes

Updated on:January 30,2024

Maximizing the potential of 3D-patient tumor avatars for next-generation precision oncology

by Terasaki Institute for Biomedical Innovation3D Patient Tumor Avatars (3D-PTAs) are part of a proposed integrative platform to provide optimal treatment selections for cancer patients. Such a platfo

Updated on: January 21,2024

Maximizing the potential of 3D-patient tumor avatars for next-generation precision oncology

by Terasaki Institute for Biomedical Innovation3D Patient Tumor Avatars (3D-PTAs) are part of a proposed integrative platform to provide optimal treatment selections for cancer patients. Such a platfo

Updated on:January 21,2024

AI in personalized cancer medicine: New therapies require flexible and safe approval conditions

by Viktoria Bosak,Dresden University of TechnologyA perspective on the US and EU regulatory system readiness for AI-enabled personalized drug and cell-based therapies in precision oncology. The

Updated on: March 05,2024

AI in personalized cancer medicine: New therapies require flexible and safe approval conditions

by Viktoria Bosak,Dresden University of TechnologyA perspective on the US and EU regulatory system readiness for AI-enabled personalized drug and cell-based therapies in precision oncology. The

Updated on:March 05,2024

Tumor microbiome linked to immunotherapy success in sarcoma patients

by Stephanie Winn,UC DavisSoft tissue sarcomas intratumoral microbiome at diagnosis may link with prognosis. (A) Representative gross examination of extremity synovial sarcoma specimen; asterisk

Updated on: January 22,2024

Tumor microbiome linked to immunotherapy success in sarcoma patients

by Stephanie Winn,UC DavisSoft tissue sarcomas intratumoral microbiome at diagnosis may link with prognosis. (A) Representative gross examination of extremity synovial sarcoma specimen; asterisk

Updated on:January 22,2024

Protein discovery sparks treatment hope for aggressive cancer

by Walter and Eliza Hall Institute of Medical ResearchTreating acute lymphoblastic leukaemia cells with the drug CX-5461 disrupts the nucleolar ribosome machinery shown by the fibrillarin protein

Updated on: March 20,2024

Protein discovery sparks treatment hope for aggressive cancer

by Walter and Eliza Hall Institute of Medical ResearchTreating acute lymphoblastic leukaemia cells with the drug CX-5461 disrupts the nucleolar ribosome machinery shown by the fibrillarin protein

Updated on:March 20,2024

Discovery suggests which thyroid cancer patients may need more aggressive treatment

by Ross Neitz,University of AlbertaOncology professor and surgeon Todd McMullen (right) says the study will help surgeons determine which patients will benefit from less aggressive treatment and

Updated on: April 18,2024

Discovery suggests which thyroid cancer patients may need more aggressive treatment

by Ross Neitz,University of AlbertaOncology professor and surgeon Todd McMullen (right) says the study will help surgeons determine which patients will benefit from less aggressive treatment and

Updated on:April 18,2024